Retinoic acid receptor beta and gamma (RAR-β and RAR-γ)

Retinoic acid receptor beta and retinoic acid receptor gamma are nuclear hormone receptors that serve as ligand-activated transcription factors. They are members of the retinoic acid receptor subfamily, encoded by RARB (beta) and RARG (gamma), which regulate gene expression in response to retinoic acids (vitamin A derivatives)[4][2]. These receptors function by heterodimerizing with retinoid X receptors (RXRs), binding to DNA response elements, and mediating processes crucial for embryonic development, cell differentiation, and homeostasis[2][4]. RAR-β and RAR-γ display both overlapping and distinct functional roles, including regulation of target gene expression under physiological and pathological conditions; they are particularly relevant in skin biology, cancer, and inflammatory diseases[1][3][4]. Drugs that modulate these receptors, such as adapalene and tretinoin, are clinically used mainly in dermatology and oncology. Safety concerns primarily relate to their teratogenic potential and side effects typical of retinoid therapy.

Other names

RAR-β (Retinoic acid receptor beta)RAR-γ (Retinoic acid receptor gamma)NR1B2 (for RAR-β)NR1B3 (for RAR-γ)Nuclear receptor subfamily 1 group B member 2 (RAR-β)Nuclear receptor subfamily 1 group B member 3 (RAR-γ)

Agonism: Ligand binding induces conformational changes increasing coactivator recruitment, activating transcription of retinoic acid response genes; Antagonism: Antagonists block ligand binding, altering coregulator exchange and preventing gene activation; Heterodimerization: Functional effects require heterodimer formation with retinoid X receptors (RXR), with complex binding to DNA response elements[2][4]